Supply Chain Pulse — 2026-07-28

The tariff story keeps twisting: Philips just posted an earnings beat partly on the back of a U.S. tariff refund — a reminder that for large device makers with the legal resources to pursue exclusions and refunds, these policies cut both ways. Meanwhile, a fresh Section 301 lawsuit argues the administration is using forced-labor tariff authority as a backdoor to reinstate duties that were previously struck down, which could reshape the cost baseline for a wide swath of imported medical supplies. Taken together with BeOne Medicines committing $300M more to U.S. manufacturing, today's stories sketch a clear picture: the tariff environment is actively rewarding suppliers who plant flags on American soil — and punishing those who haven't. If your contracts with device or pharma suppliers don't include tariff-adjustment language, that's the gap worth closing before Q4.

Quick Hits

• Philips tariff refund highlights why large suppliers should be audited for cost-recovery transparency — price increases that went up may not be coming back down automatically. (Modern Healthcare)
• Section 301 lawsuit could trigger refunds on a broad range of imported medical goods if courts find the duties were improperly applied. (Supply Chain Dive - Healthcare)
• BeOne's $1B+ U.S. manufacturing commitment adds domestic oncology drug capacity — a supply chain bright spot for a historically shortage-prone category. (Pharmaceutical Business Review)

Philips earnings beat estimates with boost from US tariff refund

Philips exceeded analyst margin expectations in its latest earnings report, citing a U.S. tariff refund as a meaningful contributor — demonstrating that large, well-resourced suppliers are actively recovering tariff costs through exclusion and refund processes. For supply chain managers, this signals that your device partners may be recouping costs you helped absorb via price increases, without those savings flowing back downstream. It's worth reviewing supplier contracts for tariff pass-through clauses and requesting transparency on any refunds applied to previously adjusted line items.

Source: Modern Healthcare

Trump's Section 301 tariffs face lawsuit seeking removal, refunds

Two businesses have filed suit arguing that the administration is improperly deploying Section 301 forced-labor tariffs as a mechanism to effectively reinstate duties that courts had previously ordered removed — a legal maneuver with potentially broad implications for imported goods including medical devices and supplies. If the lawsuit succeeds, categories of products currently carrying these levies could see duty relief and retroactive refunds, meaningfully shifting landed cost calculations. Supply chain teams should flag this case and model scenarios for affected commodity categories, particularly disposables and lower-cost devices sourced from China.

Source: Supply Chain Dive - Healthcare

BeOne to invest $300M in US manufacturing facility expansion

BeOne Medicines is adding $300M to its U.S. manufacturing footprint, bringing the oncology-focused company's total domestic investment to over $1 billion — a significant capacity expansion for cancer medicines at a time when drug tariff threats are accelerating onshoring decisions across pharma. For hospital and ASC pharmacy buyers, increased domestic production of oncology agents is a long-term positive for supply reliability, particularly given how frequently these drugs have appeared on shortage lists. The trend of manufacturers front-running potential pharma tariffs with U.S. facility commitments is worth tracking as a leading indicator of where supply stability may improve.

Source: Pharmaceutical Business Review

You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe